BioSpace News Archive

Genentech, a member of the Roche Group, announced that the Phase III MINISTONE-2 study showed that one-dose Xofluza™ was a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years old.

Novartis announced results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto® in patients with heart failure with reduced ejection fraction.

ITM Isotopen Technologien München AG and DuChemBio Co, Ltd. announced the conclusion of an exclusive licensing and development agreement for Solucin® Targeted Radionuclide Therapy in South Korea.

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that by virtue of the authorisation by the annual general meeting held on 22 May 2019, the board of directors of Hansa Biopharma AB (publ) has resolved to issue and immediately thereafter re-purchase 715,910 class C shares.

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced additional positive results from its Phase IIA clinical study2 of VALEDIA

Ardelyx, Inc. announced that it will hold a conference call tomorrow, September 3, at 8:30 am Eastern Time to review the results from the pivotal Phase 3 AMPLIFY study of tenapanor in combination with phosphate binders in patients with chronic kidney disease on dialysis whose hyperphosphatemia was not controlled with binders.

Genentech, a member of the Roche Group, announced that the Phase III BLOCKSTONE study showed preventive treatment with Xofluza™ after exposure to an infected household member significantly reduced the risk of people developing the flu by 86 percent versus placebo.

The Medicines Company announced the presentation of results from ORION-11, its first pivotal Phase 3 clinical study of inclisiran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol and the first and only cholesterol-lowering therapy in the siRNA class.

Alnylam Pharmaceuticals, Inc. provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in development for the treatment of hypercholesterolemia.

Insilico Medicine has developed GENTRL, a new artificial intelligence system for drug discovery that dramatically accelerates the process from years to days. In the industry’s first successful experimental validation of such AI technology for drug discovery in cells and animals, Insilico successfully tested the technology by creating a series of entirely new molecules capable of combating disorders like fibrosis.